Key result
Cardioneuroablation yields ~77% syncope-free survival in patients with vasodepressor vasovagal syncope.
Why the study?
Cardioneuroablation is effective for cardiac inhibitory and mixed vasovagal syncope but its therapeutic benefits in vasodepressor vasovagal syncope were unclear.
Does cardioneuroablation improve heart rate parameters and prevent syncope recurrence in patients with vasodepressor vasovagal syncope?
Cohort (n=35)
No
Does cardioneuroablation improve heart rate parameters and prevent syncope recurrence in patients with vasodepressor vasovagal syncope?
Cardioneuroablation appears safe and effective for treating vasodepressor vasovagal syncope, improving heart rate parameters and achieving a 76.92% syncope-free survival.
May support cardioneuroablation in refractory vasovagal syncope; hypothesis-generating and requires randomized confirmation before practice change.
Objective: Cardioneuroablation (CNA) is effective for cardiac inhibitory and mixed vasovagal syncope (VVS) but not for vasodepressor VVS. This study aimed to assess the therapeutic benefits of CNA in vasodepressor VVS. Methods: VVS patients hospitalized in the Department of Cardiology of Jiangxi Provincial People's Hospital were retrospectively reviewed. Holter monitoring was performed before, during, and 3 months after CNA. Changes in heart rate and atrioventricular conduction before and after ablation were compared. Results: Thirty-five patients (18 M/17F, 47.48 ± 16.49 years) were included. Median duration of syncope was 24.0 months (range, 2.5-66.0). Median number of syncope episodes before treatment was two (range, 2-4). The time domain indexes of heart rate variability, mean heart rate, maximum heart rate, and minimum heart rate were significantly higher 3 months after CNA. Mean follow-up was 11 ± 4.67 months. Recurrent syncope occurred in two patients with vasodepressor VVS, one of them with presyncope symptoms in vasodepressor type; and one patient occurred with mixed VVS, without presyncope symptoms. The syncope free survival is 76.92%. No serious complications occurred. CNA is safe and effective in the treatment of vasodepressor VVS. Conclusion: CNA is effective for treating vasodepressor VVS. Our study provides a theoretical basis for individualization of treatment in patients with vasodepressor VVS.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) conducted a cohort in Vasovagal syncope (VVS) (n=35). Cardioneuroablation vs. Baseline (pre-ablation) was evaluated on Syncope-free survival in vasodepressor VVS. Cardioneuroablation was safe and effective for treating vasodepressor vasovagal syncope, achieving a 76.92% syncope-free survival rate and significantly improving heart rate parameters.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: